Drug therapy for patients suffering from autonomic failure and neurogenic orthostatic
hypotension are scarce and not effective. If left untreated, these patients have the highest
risk of syncope, falls and fall-related injuries. The proposed study will determine the
clinical benefit of a commercially available drug, atomoxetine, to reduce symptoms associated
with neurogenic orthostatic hypotension in patients with autonomic failure.
Phase:
Phase 2
Details
Lead Sponsor:
Vanderbilt University Vanderbilt University Medical Center
Collaborators:
New York University School of Medicine NYU Langone Health